Real-world outcomes for patients with metastatic non-small cell lung cancer according to first-line treatment

Autor: Belaroussi, Y., Cousin, S., Carton, M., Lebitasy, M., Laborde, L., Laurent, C., Filleron, T., Fajole, G., Dejean, V., Parent, D., Loeb, A., Habet, T., Chambon, A., Desroys du Roure, V., Faralli, H., Lebouc, M., Pallenchier, S., Simon, G., Martin, A., Mathoulin-Pélissier, S.
Zdroj: Revue d Epidemiologie et de Sante Publique; June 2021, Vol. 69 Issue: 1, Number 1 Supplement 1 pS36-S36, 1p
Abstrakt: Metastatic non-small cell lung cancer is a disease with a poor prognosis and things may improve with the rise of immunotherapy. Clinical trials proved that immunotherapy had better results on survival than chemotherapy as first-line treatment for patients with metastatic lung cancer (MLC). Although clinical trials have strong internal validity, they suffer from restrictive selection criterions and it can be difficult to generalize to real-life patients. We aimed to evaluate if the results of survival when comparing immunotherapy with chemotherapy as first-line therapy for MLC in real-life data are similar to those from clinical trials.
Databáze: Supplemental Index
Externí odkaz: